LETpro 2.5mg Tablet is prescribed for hormone-sensitive breast cancer in post-menopausal women. It can be used alone or alongside treatments like surgery or radiation. In advanced cases, it may help prevent cancer from spreading.
Uses
- 
Hormone-sensitive breast cancer in post-menopausal women 
Benefits
- 
Reduces the risk of cancer recurrence 
- 
Supports long-term recovery after initial treatment 
- 
Slows or stops the growth of estrogen-dependent tumors 
How LETpro Works
LETpro 2.5mg Tablet is an aromatase inhibitor. It works by reducing estrogen production in the body. Since certain breast cancers require estrogen to grow, lowering estrogen levels helps control tumor growth.
How to Use
- 
Take as prescribed by your doctor 
- 
Swallow whole; do not chew, crush, or break 
- 
Can be taken with or without food, preferably at the same time every day 
- 
Follow the prescribed dose schedule for maximum benefit 
Common Side Effects
- 
Weakness, fatigue, dizziness 
- 
Joint pain, joint inflammation, back pain, bone pain 
- 
Night sweats, hot flushes, flushing, diaphoresis 
- 
Osteoporosis, bone fractures 
- 
Nausea, cough, shortness of breath 
- 
Weight gain, edema (swelling) 
- 
Hypercholesterolemia (high cholesterol) 
Precautions & Safety
- 
Alcohol: Safe 
- 
Pregnancy: Unsafe; can harm the developing baby 
- 
Breastfeeding: Unsafe; may be toxic to the baby 
- 
Driving: May cause dizziness or sleepiness; avoid driving if affected 
- 
Kidney disease: Safe if prescribed; limited info in end-stage kidney disease 
- 
Liver disease: Use with caution; dose adjustment may be needed 
Missed Dose
- 
Take the missed dose as soon as possible 
- 
If it’s almost time for the next dose, skip the missed dose 
- 
Do not double the dose 
LETpro 2.5mg Tablet is an effective therapy for post-menopausal, hormone-sensitive breast cancer, helping to slow tumor growth and reduce the risk of recurrence under medical supervision.

 
            
 
		                  


 
				 
				 
				 
				 
				 
				 
				
Reviews
There are no reviews yet.